AIMS: The aim of this study was to evaluate the efficacy and safety of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) in aiding diagnosis in lung parenchymal lesions.

METHODS: A retrospective analysis of all patients that underwent an EBUS-TBNA for a centrally located parenchymal lesion between January 2013 and December 2022.

RESULTS: A total of 128 mass lesions adjacent to central airways were sampled by EBUS-TBNA. 4 samples were excluded as the final diagnosis was unknown. Of the remaining 124 samples taken, EBUS-TBNA samples were adequate for analysis in 118 cases. The overall diagnostic hit rate was 95.2%. EBUS-TBNA detected malignancy in 101 out of 108 confirmed cases of cancer. There was one complication reported requiring procedure abandonment. The sensitivity of EBUS-TBNA in diagnosing cancer in lung parenchymal masses was 93.5%. The specificity was 100%.

EBUS histology Number
Squamous cell carcinoma 33
Adenocarcinoma 24
Non-small cell carcinoma 14
Small cell carcinoma 35
Secondary carcinoma 1
Carcinoid 1
Granulomatous inflammation 1
Reactive/benign 9
Non-diagnostic 6
Excluded from analysis 4
Total sampled 128

CONCLUSIONS: This study demonstrates that EBUS-TBNA is a safe and accurate method for the diagnosis of lung cancer in central lung parenchymal lesions.